Antibiotic susceptibility of Estrella lausannensis, a potential emerging pathogen

Microbes and Infection

Volumn 16, Issue 9, 2014, Pages 746-754

  de Barsy, Marie ^a   Bottinelli, Lavinia ^a   Greub, Gilbert ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antibiotic susceptibility; Cell culture; Chlamydia like organism; Chlamydiae

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CYCLINE; MACROLIDE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; CHILDHOOD DISEASE; CHLAMYDIA; CONTROLLED STUDY; ESTRELLA LAUSANNENSIS; GENE MUTATION; INTRACELLULAR BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PARACHLAMYDIA ACANTHAMOEBAE; QUANTITATIVE ANALYSIS; SEROPREVALENCE; UTERINE TUBE DISEASE; WADDLIA CHONDROPHILA; ACANTHAMOEBA CASTELLANII; ANIMAL; ANTIBIOTIC RESISTANCE; CHLAMYDIALES; CHLOROCEBUS AETHIOPS; CLASSIFICATION; COCULTURE; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; PRESCHOOL CHILD; RNA GENE; VERO CELL LINE;

ACANTHAMOEBA CASTELLANII; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BETA-LACTAMS; CERCOPITHECUS AETHIOPS; CHILD, PRESCHOOL; CHLAMYDIALES; COCULTURE TECHNIQUES; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENES, RRNA; HUMANS; VERO CELLS;

EID: 84908152127     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.08.003     Document Type: Article

References (28)

1. Lienard J., Croxatto A., Prod'hom G., Greub G. Estrella lausannensis, a new star in the Chlamydiales order. Microbes Infect 2011, 13:1232-1241.
2. Thomas V., Casson N., Greub G. Criblamydia sequanensis, a new intracellular Chlamydiales isolated from Seine river water using amoebal co-culture. Environ Microbiol 2006, 8:2125-2135.
3. Greub G., Raoult D. Crescent bodies of Parachlamydia acanthamoeba and its life cycle within Acanthamoeba polyphaga: an electron micrograph study. Appl Environ Microbiol 2002, 68:3076-3084.
4. Moulder J.W. Interaction of chlamydiae and host cells invitro. Microbiol Rev 1991, 55:143-190.
5. Rusconi B., Lienard J., Aeby S., Croxatto A., Bertelli C., Greub G. Crescent and star shapes of members of the Chlamydiales order: impact of fixative methods. Ant Van Leeuwenhoek 2013, 104:521-532.
6. Kebbi-Beghdadi C., Batista C., Greub G. Permissivity of fish cell lines to three Chlamydia-related bacteria: Waddlia chondrophila, Estrella lausannensis and Parachlamydia acanthamoebae. FEMS Immunol Med Microbiol 2011, 63:339-345.
7. Casson N., Greub G. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes. Int J Antimicrob Agents 2006, 27:541-544.
8. Goy G., Greub G. Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. Antimicrob Agents Chemother 2009, 53:2663-2666.
9. Hammerschlag M.R., Qumei K.K., Roblin P.M. Invitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992, 36:1573-1574.
10. Smelov V., Perekalina T., Gorelov A., Smelova N., Artemenko N., Norman L. Invitro activity of fluoroquinolones, azithromycin and doxycycline against Chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms. Eur Urol 2004, 46:647-650.
11. Casson N., Posfay-Barbe K.M., Gervaix A., Greub G. New diagnostic real-time PCR for specific detection of Parachlamydia acanthamoebae DNA in clinical samples. J Clin Microbiol 2008, 46:1491-1493.
12. Maurin M., Bryskier A., Raoult D. Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae. Antimicrob Agents Chemother 2002, 46:3065-3067.
13. Nakamura Shinichi Mechanisms of quinolone resistance. J Infect Chemother 1997, 3:128-138.
14. Coles A.M., Reynolds D.J., Harper A., Devitt A., Pearce J.H. Low-nutrient induction of abnormal chlamydial development: a novel component of chlamydial pathogenesis?. FEMS Microbiol Lett 1993, 106:193-200.
15. Raulston J.E. Response of Chlamydia trachomatis serovar E to iron restriction invitro and evidence for iron-regulated chlamydial proteins. Infect Immun 1997, 65:4539-4547.
16. Jacquier N., Frandi A., Pillonel T., Viollier P., Greub G. Cell wall precursors are required to organize the chlamydial division septum. Nat Commun 2014, 5:3578.
17. Vester B., Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001, 45:1-12.
18. Binet R., Bowlin A.K., Maurelli A.T., Rank R.G. Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. Antimicrob Agents Chemother 2010, 54:1094-1101.
19. Binet R., Maurelli A.T. Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. Antimicrob Agents Chemother 2007, 51:4267-4275.
20. Dreses-Werringloer U., Padubrin I., Zeidler H., Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection invitro. Antimicrob Agents Chemother 2001, 45:3001-3008.
21. Hammerschlag M.R., Gleyzer A. Invitro activity of a group of broad-spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother 1983, 23:493-494.
22. Samra Z., Rosenberg S., Soffer Y., Dan M. Invitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001, 39:177-179.
23. Smelov V., Krylova T., Smelova N., Norman L. Azithromycin treatment follow-up: antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis. Int J Antimicrob Agents 2004, 23(Suppl. 1):S79-S82.
24. Nilius A.M., Shen L.L., Hensey-Rudloff D., Almer L.S., Beyer J.M., Balli D.J., et al. Invitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 2003, 47:3260-3269.
25. Miyashita N., Niki Y., Kishimoto T., Nakajima M., Matsushima T. Invitro and invivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997, 41:1331-1334.
26. Senn L., Hammerschlag M.R., Greub G. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother 2005, 6:2281-2290.
27. Chirgwin K., Roblin P.M., Hammerschlag M.R. Invitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother 1989, 33:1634-1635.
28. Kuo C.C., Grayston J.T. Invitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob Agents Chemother 1988, 32:257-258.